Lexaria Bioscience Corp. is Changing the Future of Drug Delivery

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Lexaria Bioscience Corp. LEXX is developing emerging technology that promotes faster delivery of drugs into the bloodstream, among other patented innovative health initiatives, making the company a visible player in the $50 billion pharmaceutical drug delivery category. Lexaria’s DehydraTECH™ can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.

Lexaria Has Laid the Foundation

Lexaria is a research-driven company specifically employing its patented drug delivery technology, making an innovative move to stand out among companies looking to invest in improving drug delivery systems, including GW Pharmaceuticals GWPH, Aphria, Inc. APHA and Cannabics Pharmaceuticals CNBX.

Lexaria has done their due diligence, through studies in vivo, in vitro, human clinical trials, liquid chromatography high-resolution mass spectrometry, nuclear magnetic resonance, and Fourier Transform Infrared (“FTIR”) spectroscopy to study the transformative technology coming from Lexaria.

Shaking Up the Current Drug Delivery Mechanism

Lexaria’s disruptive and cost effective technology DehydraTECH™ improves the mechanism that active pharmaceutical ingredients (APIs) use to enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dose required for effective treatment. The new cost-effective technology leads to healthier administration methods and a higher effectiveness per unit of ingestible drugs and other beneficial molecules.

The company’s TurboCBD™ hemp oil capsules, specially formulated with American Ginseng and Ginkgo Biloba and triple tested for purtiy, are used to support enhanced focus and memory and reduce stress and fatigue using its patented absorption technology. The capsules are American made without the use of organic solvents, leaving no hemp oil aftertaste and are also vegan, gluten-free, sugar-free, and nut-free. The capsules will soon be made available for sale through California medical cannabis dispensaries and other select locations.


Vast Array of Patents

Lexaria’s first patent was issued by the USPTO in October 2016 (US 9,474,725 B1) and provides 20 years of patent protection until June 2034Multiple patents have beenawarded since then with more expected on the horizon.

DehydraTECH™ has pending patents in 40 countries around the world including protection for nicotine delivery, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors and tobacco. Last year, the company reported its most urgent investigations being related to applying DehydraTECH™ to existing antiviral and other drugs useful in the fight against the Coronavirus.


Lexaria announced on February 1, 2021 an ambitious R&D strategy to advance DehydraTECHTM towards commercial exploitation in two main sectors: high blood pressure and anti-viral drugs.

Fiscal Growth

Lexaria reported fiscal year financial highlights including:

  • A January closing of an $11.04M public offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants
  • 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit
  • Performance at the end of November 2020
    • Total Assets of $2,174,320
    • Quarterly revenue of $295,656
    • Gross quarterly profits of $231,178

Chris Bunka, chairman and CEO of Lexaria Bioscience said, "Lexaria is starting its most impactful year ever; we've already up listed to the Nasdaq and completed an $11 million capital raise to enhance the development of DehydraTECH.”

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

Posted In: BiotechNewsMarketsGeneral